GlaxoSmithKline won’t buy AstraZeneca

Comment on this story
GlaxoSmithKlinePharma REUTERS

Britain's biggest drugmaker GlaxoSmithKline has no interest in buying smaller rival AstraZeneca, GSK's chief executive said on Thursday in response to a shareholder question at the firm's annual meeting.

AstraZeneca, Britain's second-biggest drugmaker, has suffered repeated drug development setbacks, stoking fears about its long-term prospects given a complete reliance on prescription medicines at a time when rivals have diversified.

The company's future is in flux, following the planned early exit of its CEO David Brennan from June 1, leading some analysts to speculate it might become a takeover target.

GSK CEO Andrew Witty, however, told investors at the company's AGM that buying a big company like AstraZeneca would be “very distracting”.

The question of GSK buying AstraZeneca was raised by a small shareholder, who argued it would be more sensible than GSK's $2.6 billion bid for Human Genome Sciences Inc.

GSK made an unsolicited bid for long-time partner Human Genome Sciences last month, which the U.S. biotech company rejected.

Witty has stated in the past that he does not envisage large acquisitions but is interested in bolt-on buys. - Reuters

sign up

Comment Guidelines

  1. Please read our comment guidelines.
  2. Login and register, if you haven’ t already.
  3. Write your comment in the block below and click (Post As)
  4. Has a comment offended you? Hover your mouse over the comment and wait until a small triangle appears on the right-hand side. Click triangle () and select "Flag as inappropriate". Our moderators will take action if need be.

  5. Verified email addresses: All users on Independent Media news sites are now required to have a verified email address before being allowed to comment on articles. You are only required to verify your email address once to have full access to commenting on articles. For more information please read our comment guidelines